MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Cancer Stemness

  • Home
  • Cancer Stemness
RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma
Posted inGastroenterology news Oncology

RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma

Posted by By MedXY 07/31/2026
RIPPLY1 suppresses cancer stemness by targeting TBX19, improving prognosis in CTNNB1-mutated hepatocellular carcinoma through inhibition of tumor progression.
Read More
Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment
Posted inClinical Updates Oncology Specialties

Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment

Posted by By MedXY 09/29/2025
A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.
Read More
  • Enhanced Risk Stratification for Pediatric Tracheostomy Hospitalizations: Evaluating a Novel Tracheostomy-Specific Tier System
  • Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children
  • Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications
  • Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave
  • Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top